Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 10/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379681 | 1.00 | ALDH1A1 (0.40) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL23509267 | 0.84 | ALDH1A1 (0.44) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL23918727 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL23910322 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL23910320 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL23910338 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL23918726 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL24345588 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL30804820 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TSHRMEN1KMT2ACASP3 | |
| SCHEMBL23918400 | 0.77 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-3700907-B1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX5 | ALDH1A1 1120/4885TSHR 2897/4885MEN1 2887/4885 |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX1, P2RX5 | ALDH1A1 1149/4885TSHR 3113/4885MEN1 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.